College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha W. University, Seoul, 120-750, Republic of Korea.
J Cell Biochem. 2018 Jan;119(1):347-357. doi: 10.1002/jcb.26186. Epub 2017 Jun 30.
The executioner caspase-3 has been proposed as a pharmacological intervention target to preserve degenerating dopaminergic (DA) neurons because apoptotic mechanisms involving caspase-3 contribute, at least in part, to the loss of DA neurons in patients and experimental models of Parkinson's disease (PD). Here, we determined that genetic intervention of caspase-3 was sufficient to prevent cell death against oxidative stress (OS), accompanied by unexpected severe mitochondrial dysfunction. Specifically, as we expected, caspase-3-deficient DA neuronal cells were very significantly resistant to OS-induced cell death, while the activation of the initiator caspase-9 by OS was preserved. Moreover, detailed phenotypic characterization of caspase-3-deficient DA cells revealed severe mitochondrial dysfunction, including an accumulation of damaged mitochondria with a characteristic swollen structure and broken cristae, reduced membrane potential, increased levels of reactive oxygen species (ROS), and deficits in mitochondrial oxidative phosphorylation (OXPHOS) enzymes. Of great interest, we found that mitochondrial biogenesis was dramatically decreased in caspase-3-deficient DA cells, whereas their capability of mitophagy was normal. In accordance with this observation, caspase-3 gene knock down (KD) resulted in dramatically decreased expression of the key transcriptional activators of mitochondrial biogenesis, such as Tfam and Nrf-1, implicating a non-apoptotic role of procaspase-3 in mitochondrial biogenesis. Therefore, a prolonged anti-apoptotic intervention targeting caspase-3 should be considered with caution due to the potential adverse effects in mitochondria dynamics resulting from a novel potential functional role of procaspase-3 in mitochondrial biogenesis via regulating the expression of mitochondrial biogenesis activators. J. Cell. Biochem. 119: 347-357, 2018. © 2017 Wiley Periodicals, Inc.
执行器胱天蛋白酶-3 已被提议作为一种药理学干预靶点,以保护退化的多巴胺能 (DA) 神经元,因为涉及胱天蛋白酶-3 的凋亡机制至少部分导致了帕金森病 (PD) 患者和实验模型中 DA 神经元的丧失。在这里,我们确定胱天蛋白酶-3 的遗传干预足以防止氧化应激 (OS) 引起的细胞死亡,同时伴有意外的严重线粒体功能障碍。具体来说,正如我们所预期的,胱天蛋白酶-3 缺陷型 DA 神经元细胞对 OS 诱导的细胞死亡非常显著具有抗性,而 OS 对起始胱天蛋白酶-9 的激活得以保留。此外,对胱天蛋白酶-3 缺陷型 DA 细胞的详细表型特征分析显示出严重的线粒体功能障碍,包括受损线粒体的积累,其特征为肿胀结构和破裂嵴,膜电位降低,活性氧 (ROS) 水平升高,以及线粒体氧化磷酸化 (OXPHOS) 酶的缺陷。有趣的是,我们发现胱天蛋白酶-3 缺陷型 DA 细胞中线粒体生物发生显著减少,而它们的线粒体自噬能力正常。与这一观察结果一致,胱天蛋白酶-3 基因敲低 (KD) 导致线粒体生物发生的关键转录激活因子,如 Tfam 和 Nrf-1 的表达显著降低,暗示了前胱天蛋白酶-3 在调节线粒体生物发生的关键转录激活因子的表达方面在线粒体生物发生中具有非凋亡作用。因此,由于前胱天蛋白酶-3 在通过调节线粒体生物发生激活因子的表达在线粒体生物发生中具有新的潜在功能作用,因此针对胱天蛋白酶-3 的延长抗凋亡干预应该谨慎考虑,因为这可能会对线粒体动力学产生不利影响。J. Cell. Biochem. 119: 347-357, 2018。© 2017 Wiley Periodicals, Inc.